{
    "clinical_study": {
        "@rank": "23255", 
        "acronym": "VANCS II", 
        "arm_group": [
            {
                "arm_group_label": "Norepinephrine", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Vasopressin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Although arginine vasopressin has been used as an additional drug in refractory shock in\n      worldwide clinical practice, there are no prospective studies using it as a first choice\n      therapy in patients with cancer and septic shock.\n\n      The aim of this study is assess if the use of arginine vasopressin would be more effective\n      on treatment of septic shock in cancer patients than norepinephrine, decreasing the\n      composite end point of mortality and organ failure in 28 days."
        }, 
        "brief_title": "Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Septic Shock", 
        "condition_browse": {
            "mesh_term": [
                "Shock", 
                "Shock, Septic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Solid neoplasm needing ICU\n\n          -  Septic Shock according standard criteria\n\n        Exclusion Criteria:\n\n          -  Younger than 18 years;\n\n          -  Pregnancy;\n\n          -  Raynaud's phenomenon, systemic sclerosis or vasospastic diathesis;\n\n          -  Severe hyponatremia (Na<130mEq/L);\n\n          -  Acute mesenteric ischemia;\n\n          -  Acute myocardial infarction;\n\n          -  Cardiogenic shock;\n\n          -  Current use of vasopressor before randomization\n\n          -  Expected ICU stay less than 24 hours\n\n          -  Enrolled in another study;\n\n          -  Refusal to consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718613", 
            "org_study_id": "91762"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vasopressin", 
                "description": "Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement", 
                "intervention_name": "Vasopressin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Norepinephrine", 
                "description": "Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement", 
                "intervention_name": "Norepinephrine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vasopressins", 
                "Arginine Vasopressin", 
                "Norepinephrine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 2, 2012", 
        "location": {
            "contact": {
                "email": "czambolim@yahoo.com.br", 
                "last_name": "Cristiane M Zambolim, MD", 
                "phone": "+55-11-38933267"
            }, 
            "facility": {
                "address": {
                    "city": "Sao Paulo", 
                    "country": "Brazil", 
                    "state": "Sao Paulo/SP", 
                    "zip": "01246000"
                }, 
                "name": "Instituto do Cancer do Estado de Sao Paulo"
            }, 
            "investigator": {
                "last_name": "Cristiane M Zambolim, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients", 
        "overall_contact": {
            "email": "czambolim@yahoo.com.br", 
            "last_name": "Cristiane M Zambolim, MD", 
            "phone": "+11-55-3893-3267"
        }, 
        "overall_contact_backup": {
            "email": "ludhmila@usp.br", 
            "last_name": "Ludhmila A Hajjar, MD, PhD", 
            "phone": "+11-55-3893-3267"
        }, 
        "overall_official": {
            "affiliation": "Department of Anesthesia and Critical Care, Intensive Care Unit - ICESP", 
            "last_name": "Cristiane M Zambolim, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Mortality from all causes in 28-day follow-up", 
            "measure": "28-day mortality", 
            "safety_issue": "Yes", 
            "time_frame": "28-day from randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718613"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
            "investigator_full_name": "Cristiane Maciel Zambolim", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Mortality from all causes 90 days after randomization", 
                "measure": "90-days mortality", 
                "safety_issue": "Yes", 
                "time_frame": "90 days after randomization"
            }, 
            {
                "description": "Days alive and free of mechanical ventilation at 28-day follow-up", 
                "measure": "Days alive and free of mechanical ventilation", 
                "safety_issue": "Yes", 
                "time_frame": "28 days after randomization"
            }, 
            {
                "description": "Days alive and free of any type of vasopressor agent at 28-day follow-up", 
                "measure": "Days alive and free of vasopressors", 
                "safety_issue": "Yes", 
                "time_frame": "28 days after randomization"
            }, 
            {
                "description": "requirement of dialysis of hemofiltration at 28-day follow-up", 
                "measure": "Days alive and free of renal replacement therapy", 
                "safety_issue": "Yes", 
                "time_frame": "28 days after randomization"
            }, 
            {
                "description": "Days alive and free of organ failure according the sequential organ failure assessment (SOFA)", 
                "measure": "Days alive and free of organ failure", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours after ICU admission"
            }, 
            {
                "description": "Days alive and free of organ failure according to sequential organ failure assessment (SOFA)", 
                "measure": "Days alive and free of organ failure", 
                "safety_issue": "Yes", 
                "time_frame": "96 hours after randomization"
            }, 
            {
                "measure": "Costs", 
                "safety_issue": "No", 
                "time_frame": "Hospital discharge"
            }
        ], 
        "source": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}